|
|
|
|
|
|
|
Articles by keyword
medicines
Live from the TPP: IP chapter shows no sign of resolution, end of negotiation in 2013 highly unlikely
| 21-May-2013
There is a strong sense in the halls of the current TPP negotiation that the end is not in sight. And one of the primary reasons s a lack of consensus on intellectual property and pharmaceuticals issues, reports Infojustice from Lima.
Investors’ IP rights unbound: The danger of investment clauses to access to medicines
| 25-April-2013
Although access to medicines activists have been wise to focus our attention intently on convincing low- and middle-income countries to adopt and use all possible TRIPS-compliant flexibilities and to oppose the TRIPS-plus IP chapters in free trade agreements, we have neglected to interrogate another chapter in free trade agreements and bilateral investment treaties that perhaps pose an even greater threat to our collective access to medicines – investment chapters.
India-EU FTA won’t hit generic drugs industry: EU envoy
| 13-April-2013
The much-hyped bilateral trade and investment agreement (BTIA) between India and the European Union (EU) would not impact the Indian generic drugs industry or lead to a change in the country’s patent law, João Cravinho, EU ambassador to India, said on Friday.
Indios rechazan la firma de un TLC con Unión Europea
| 12-April-2013
Centenares de activistas y empleados del sector de salud de La India protagonizaron el miércoles una manifestación multitudinaria para protestar contra la posible firma de un Tratado de Libre Comercio (TLC) entre su país y la Unión Europea (UE).
India-EU FTA will imperil lives, local industry, say activists
| 11-April-2013
A large number of people living with HIV, cancer patients and health activists took to the streets of Delhi today asking government of India not to sign a Free Trade Agreement (FTA) with the European Union (EU) as it would be detrimental to the interests of tens of thousands of people like them in the country.
Cambodian people’s statement on the EU-India free trade agreement on generic drugs
| 10-April-2013
We, Cambodian garment workers, sex workers, entertainment workers, people living with HIV, LGBTs, university students, feminists and human right activists from different networks and organisations came together to express our concern about the threat posed by the forthcoming EU-India free trade agreement to the lives of millions of people in Cambodia and many other developing countries across the world.
Semaine internationale d’action contre les accords de libre-échange
| 10-April-2013
Du 9 au 15 avril 2013, les activistes et associations de lutte contre le sida et de défense de la santé du monde entier s’unissent pour lutter contre la stratégie commercial mortelle de la Commission et envoient a l’europe un message clair : les attaques contre les médicaments génériques doivent cesser maintenant
L’accord de libre-échange entre l’UE et l’Inde met des millions de vies en danger
| 10-April-2013
Des militants de différents pays européens et des euro-députés se réunissent devant le Parlement européen pour réclamer l’abandon de dispositions mettant en danger l’accès aux médicaments.
Join the rally to oppose EU-India FTA!
| 9-April-2013
Around 2000 people including people living with HIV (PLHIV), patient groups and public health activists will take to the streets and rally from Barakhamba road to Jantar Mantar at 11.00 am on 10 April 2013 to voice concerns and protest against harmful provisions being pushed by the EU-India FTA negotiations
Manmohan Singh must learn from the Novartis judgement
| 2-April-2013
Will Manmohan Singh understand the clear purpose behind the national sentiment around the Supreme Court judgment on Novartis’ cancer drug Glivec? If he does, he should take a relook at the India-EU Free Trade Agreement that is cooking in his back-room.
European Union sets tough conditions under FTA
| 1-April-2013
The gains accruing to the Indian generic drugs industry as a result of the Supreme Court judgement on the Novartis case may be lost if India accepts demands by the European Union (EU) under the proposed free trade agreement (FTA) between the two sides.
Indian pharma sector fears India-European Union FTA could imperil local industry
| 27-March-2013
Drugmakers and healthcare activists are worried that the India-European Union Free Trade Agreement (FTA), which is in the works, may contain a provision that could imperil local industry and have urged the government to keep patent infringement issues out of FTAs.
European Union-India FTA may hit generic medical industry
| 21-March-2013
The free trade agreement that European Union is pushing India to sign could put an end to India’s status as the pharmacy of the developing providing affordable medicines, especially HIV drugs to countries like Brazil, Thailand, South Africa, Zimbabwe and several others. The negotiations with EU are on at a feverish pace this week in Brussels even before the parliamentary standing committee looking into the free trade agreements (FTAs) has submitted its report. 
The TPP negotiators are making decisions that will affect at least 600 million people, and potentially hundreds of millions more, in complete secrecy, and this is unacceptable.
EU-Thailand FTA negotiations: What fate for access to medicines?
| 6-March-2013
Health Action International Europe, Oxfam and Action against AIDS Germany have serious concerns over the repercussions the EU-Thailand FTA will have on access to medicines in Thailand and the region. 
As closed-door talks for the Trans-Pacific Partnership Agreement resume in Singapore this week, international medical humanitarian organization Médecins Sans Frontières calls on the US government to end its stall tactics and revise its proposals for what otherwise promises to be the most harmful trade deal ever for access to medicines in developing countries.
TLC con UE hace peligrar los genéricos contra el sida en Tailandia, según ONG
| 1-March-2013
La fundación AIDS Access afirmó hoy que el tratado de libre comercio (TLC) entre Tailandia y la Unión Europea (UE) pondrá en peligro el acceso de los enfermos de sida a los medicamentos genéricos en el país asiático. 
La Cámara Nacional de la Industria Farmacéutica (Canifarma) evaluó en diciembre de 2012 los textos –que no son públicos– sobre propiedad intelectual del Acuerdo de Asociación Transpacífico (TPP por sus siglas en inglés) y su conclusión fue inequívoca: en ellos se busca extender los tiempos de duración de las patentes de medicamentos. La Asociación Mexicana de Laboratorios Farmacéuticos (Amelaf) ya había revelado las intenciones de las grandes farmacéuticas de Estados Unidos. 
Days before leaders of the European Union arrived in Norway to collect this year’s Nobel Peace prize, Thai public health activists sent a letter to the northern powerhouse, warning that the EU’s 2012 accolades face a credibility test in this Southeast Asian country. 
As free trade talks with the European Union reach the endgame, Ottawa is signalling it is prepared to give the Europeans at least part of what they asked for on drug patents — a move that could cost Canadians up to $900 million a year. |
L’accord entre l’Union Européenne et l’Inde menace l’accès aux traitements en Afrique du Nord et au Moyen-Orient
| 12-April-2013
|
